GIOSTAR has an ability to treat several devastating Immunological diseases and Blood related diseases. These include Diabetes Type I and Type II, Lupus, Multiple Sclerosis, Crohn’s disease, Vasculitis, Scleroderma, Myasthenia Gravis, Sickle Cell Anemia, Leukemia, Lymphoma, Thalassemia and developing the therapies for Alzheimer’s, Autism, Anti-Aging Treatments, Parkinson’s disease, Cancer, Heart and Retinal Degeneration, Amyotrophic Lateral Sclerosis, Neuropathy, Osteoarthritis, Paralysis, Strokes, Spinal Cord Injuries, Skin Burns and Spinal Muscular Atrophy (SMA).
GIOSTAR is in process of opening Institutes of Regenerative Medicine and Dedicated Stem Cell Treatment hospitals/centers in Asia, Middle East, Africa, North and South America and Europe. The proposed facilities will be developed with the international support from public and private sectors grants and investments to provide stem cell based therapy for those suffering from degenerative or genetic diseases.
INSTITUTE OF REGENERATIVE MEDICINE AND STEM CELL TREATMENT HOSPITALS
GIOSTAR is using adult stem cell for its autologous and allogeneic stem cells transplant to treat patients, following the highest medical standards. The adult stem cell technology is well developed and being used regularly in clinical practice. Our clinicians are licensed to treat the patients using autologous (their own) and allogeneic (from others) adult stem cells for certain diseases. We are the leading private organization, which has state of art excellence in extraction of stem cell from a human body and use it for therapy. Our clinicians are treating the patients regularly using adult stem cells since 2000.
GIOSTAR is a coalition of esteemed and illustrious scientific minds in the field of stem cell science, genetics and cancer research. For over 15 years GIOSTAR team of scientists and clinicians have been involved in the development and utilization of stem cell based clinical protocols related to stem cell transplants.
The GIOSTAR team includes international leaders in the field of adult stem cell, embryonic stem (ES) cells and Induced Pluripotent Stem (IPS) cells research and technologies. The GIOSTAR team is the first in demonstrating the significance of ES cell use for the development of therapies for several degenerative diseases related to tissue and organs. The publications of these therapies have been thoroughly investigated and documented by many noted journals of medicine. GIOSTAR is leading the most advanced research in the field of ES cells and IPS cells to develop new therapies for future clinical use.
GIOSTAR advanced Stem Cell science will be used to treat qualified patients on needed basis.